We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
-1.35%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$206M
AUM Growth
+$10.1M
Cap. Flow
+$2.27M
Cap. Flow %
1.11%
Top 10 Hldgs %
63.37%
Holding
47
New
7
Increased
9
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$14.9M
2
VSTM icon
Verastem
VSTM
+$10.7M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.1M
4
REPL icon
Replimune Group
REPL
+$7.3M
5
NUVB icon
Nuvation Bio
NUVB
+$5.58M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$10.6M
2
OPTN
OptiNose
OPTN
+$3.9M
3
VRNA
Verona Pharma
VRNA
+$2.99M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$2.46M
5
MDWD icon
MediWound
MDWD
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$416M
$29M 14.1%
2,900,389
+250,000
+9% +$3.55M
VSTM icon
2
Verastem
VSTM
$536M
$15.9M 7.75%
2,644,517
+1,744,517
+194% +$10.7M
XERS icon
3
Xeris Biopharma Holdings
XERS
$1.45B
$13.7M 6.66%
2,495,986
-609,009
-20% -$2.46M
MYO icon
4
Myomo
MYO
$38.6M
$13M 6.32%
2,703,661
-295,284
-10% -$1.68M
IDYA icon
5
IDEAYA Biosciences
IDYA
$3.5B
$11.5M 5.58%
+700,000
New +$14.9M
FENC icon
6
Fennec Pharmaceuticals
FENC
$344M
$10.9M 5.28%
1,782,844
+522,968
+42% +$3.36M
URGN icon
7
UroGen Pharma
URGN
$2B
$10.5M 5.11%
950,000
+80,000
+9% +$853K
OCUL icon
8
Ocular Therapeutix
OCUL
$1.85B
$8.93M 4.34%
1,218,700
+90,000
+8% +$692K
ABEO icon
9
Abeona Therapeutics
ABEO
$369M
$8.6M 4.18%
1,805,817
+427
+0% +$2.32K
REPL icon
10
Replimune Group
REPL
$455M
$8.29M 4.03%
850,000
+590,000
+227% +$7.3M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.2B
$8.02M 3.9%
+595,000
New +$10.1M
MDWD icon
12
MediWound
MDWD
$181M
$7.87M 3.83%
506,893
-121,157
-19% -$2.17M
SVRA icon
13
Savara
SVRA
$1.14B
$7.35M 3.58%
2,654,944
– –
VRNA
14
DELISTED
Verona Pharma
VRNA
$6.35M 3.09%
100,000
-50,000
-33% -$2.99M
NSPR icon
15
InspireMD
NSPR
$31.5M
$6.12M 2.98%
2,274,990
-220,793
-9% -$625K
HELP
16
Cybin Inc
HELP
$505M
$5.14M 2.5%
810,918
– –
NUVB icon
17
Nuvation Bio
NUVB
$2.33B
$4.31M 2.1%
+2,451,500
New +$5.58M
PROF
18
Profound Medical
PROF
$263M
$4.03M 1.96%
692,185
– –
TRVI icon
19
Trevi Therapeutics
TRVI
$2.61B
$3.86M 1.87%
612,901
-449,599
-42% -$2.14M
PHVS icon
20
Pharvaris
PHVS
$2.37B
$3.51M 1.71%
+223,627
New +$3.77M
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$3.51M 1.71%
303,864
– –
PYPD icon
22
PolyPid
PYPD
$83.8M
$2.76M 1.34%
1,018,021
– –
DFTX
23
Definium Therapeutics
DFTX
$5.91B
$2.46M 1.19%
+420,000
New +$3.01M
CMPS
24
Compass Pathways
CMPS
$1.56B
$2.35M 1.15%
823,286
+115,661
+16% +$444K
OPTN
25
DELISTED
OptiNose
OPTN
$2.35M 1.14%
256,190
-620,806
-71% -$3.9M
1
2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Rosalind Advisors held 47 positions worth $206M, up 5.1% from $196M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Rosalind Advisors's Q1 2025 filing shows 7 new, 9 increased, 12 reduced and 13 closed positions. Its largest new stake was IDEAYA Biosciences: 700,000 shares worth $11.5M. The largest sale was Chimerix, Inc., an estimated $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • Rosalind Advisors's largest Q1 2025 buy was IDEAYA Biosciences: 700,000 shares worth $11.5M.
  • Rosalind Advisors added most to Verastem in Q1 2025, an estimated $10.7M increase.
  • Rosalind Advisors's biggest Q1 2025 reduction was OptiNose, cutting an estimated $3.9M.
  • Rosalind Advisors fully exited Chimerix, Inc. in Q1 2025, selling an estimated $10.6M.
  • Rosalind Advisors's ten largest holdings make up 63% of its $206M portfolio in Q1 2025.
  • Rosalind Advisors opened 7 new positions and closed 13 in Q1 2025.
  • Rosalind Advisors's portfolio value rose 5.1% quarter-over-quarter to $206M.

Based on Rosalind Advisors's 13F filing for Q1 2025, filed 14 May 2025.